Benzinga | Mar 10, 2021 09:08AM EST

Natera And Genentech Initiate Phase III Trial Using Signatera As A Companion Diagnostic For Atezolizumab In Early-Stage Muscle-Invasive Bladder Cancer

AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the first patient has been screened in a new phase III clinical trial that uses its tumor-informed, personalized molecular residual disease (MRD) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma (MIUC) patients eligible for investigational treatment with Genentech's, a member of the Roche group, cancer immunotherapy drug atezolizumab (Tecentriq)(r).